Discussion
obesity, reduced cardiac chamber size and stroke, Pre-HFpEF, cardiac and vascular stiffness, diabetes
OBESITY, MYOCARDIAL INFARCTION, ADVERSE EFFECTS, HYPERTENSION, DIABETES
Pre-HFpEF is common, has no specific therapy aside from cardiovascular risk factor management, and is growing due to aging populations, increased prevalence of diabetes, persistent hypertension, and obesity. The 2022 AHA/ACC guidelines for heart failureThe effect of neprilysin inhibition on the primary end point in PARABLE was unexpected. Increases in maximal LAVI and left ventricular end diastolic volume index are ordinarily associated with a poorer outlook. While treatment with sacubitril/valsartan vs valsartan in a post–myocardial infarction population did not alter cardiac volumes,The aging myocardium of sedentary adults is associated with cardiac and vascular stiffness, reduced cardiac chamber size and stroke volumes.Conversely, increased cardiac chamber volumes in PARABLE could reflect adverse effects of neprilysin inhibition, which is known to preserve proremodeling vasoconstrictor peptides.